• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » RPS to Raise $100 Million in IPO

RPS to Raise $100 Million in IPO

June 23, 2010
CenterWatch Staff

ReSearch Pharmaceutical Services (RPS) plans an initial public offering in the U.S. on the Nasdaq exchange. The Fort Washington, Pa.-based contract research organization (CRO ) seeks to raise $100 million from the IPO.

RPS, which prefers to be called a pharmaceutical research organization, had been traded for two years on the London Stock Exchange Alternative Investment Market (AIM) after going public by reverse merger in August of 2007. It delisted in September of 2009. 

Michael Martorelli, director with Fairmount Partners and a long-time observer of the CRO industry, said going public in the U.S. could prove more fruitful for the 16-year-old, 2,360-employee CRO. 

“This market is definitely more liquid, more visible,” Martorelli said. “RPS didn't trade that much when it was on the AIM, so they're trying it again here.” 

RPS's June 18 filing with the U.S. Securities and Exchange Commission did not say how many shares the company planned to sell, nor did it reveal their expected price. RPS could not be queried since it's in a quiet period that's customary when a company goes public. 

Martorelli said the move is not a surprise; RPS was among a handful of companies that industry observers thought might go public soon. The others, he said, include Cetero Research and INC Research and Medpace. “They've all been rumored to be lined up and ready to go,” he said. 

Martorelli said now is not a bad time for a CRO to go public. “(CRO) stocks are not ridiculously cheap or ridiculously expensive, and the industry seems to be coming back from its down period of late '08 and into '09. It seems like an okay time,” he said. 

Though RPS posted a net loss of $73,000 for the first quarter of 2010, down from income of $500,000 for the same quarter a year earlier, Martorelli describes the firm as financially sound. “They've been nicely profitable for a couple years, and growing,” he said.  

With the money RPS raises, it may makes more acquisitions, suggested Martorelli. In 2009, RPS bought Chinese CRO Paramax International for $1 million, adding to three European CROs purchased during 2008. Just before that, RPS had expanded rapidly into Latin America. RPS is a CRO that provides functional outsourcing across a client's entire pipeline in a specific region. 

Jefferies & Co., William Blair & Co. and Lazard Capital Markets are underwriting the IPO. RPS plans to list its shares on Nasdaq under the symbol "RPSE." 

Will this IPO– the first in a long while among CROs—spark a trend, especially those who are rumored to be ready? “This will be a good test,” Martorelli said.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing